Latest InSightec Ltd. Stories
TIRAT CARMEL, Israel, July 13, 2011 /PRNewswire/ -- Initial Results are Encouraging, Spurring Hope for a Treatment Option With a Lower Rate of Complications InSightec Ltd., the global leader in MR-guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that 23 patients with organ confined low risk prostate cancer have already been treated with its ExAblate(R) system in...
TEL AVIV, Israel, November 25, 2010 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit") announced today that, further to its announcement dated September 13, 2010, it has successfully closed the transaction with Enter Holdings 1 Ltd.
TIRAT CARMEL, Israel, September 29, 2010 /PRNewswire/ -- InSightec Ltd., the global leader in MR guided Focused Ultrasound technology (MRgFUS) announced today that it will be launching ExAblate(R) One for the treatment of uterine fibroids, adenomyosis and research options in women's health and the ExAblate(R) OR system as the Operating Room of the future at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2010 meeting. (Logo:...
TIRAT CARMEL, Israel, August 31, 2010 /PRNewswire/ -- InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients.
TEL AVIV, Israel, August 31, 2010 /PRNewswire-FirstCall/ -- - ExAblate(R) MR Guided Focused Ultrasound System is Being Used for the First Time for Non-invasive Treatment of Prostate Cancer - Seven Patients With Prostate Confined Low Risk Cancer Treated in Clinical Trials Elbit Imaging Ltd.
TEL AVIV, January 14 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit" "Company") that its subsidiary, InSightec Ltd., announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the company's ExAblate(R) MR-guided Focused Ultrasound (MRgFUS) system for the treatment of women with uterine fibroids. ExAblate is currently the only noninvasive treatment for uterine fibroids approved for use in Japan. InSightec Ltd.
TIRAT CARMEL, Israel, January 13 /PRNewswire/ -- - InSightec's ExAblate System Uses Magnetic Resonance-guided Focused Ultrasound to Perform Uterine Procedures Without Incisions InSightec Ltd.
- A transitional zone between two communities containing the characteristic species of each.